Drug Profile
Oxyntomodulin - Merck
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Anorectics; Antihyperglycaemics; Gastrointestinal hormones; Obesity therapies; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 01 Jul 2011 Merck completes a phase I trial in Type-2 diabetes mellitus in Netherlands (NCT01373450)
- 10 Jun 2010 Merck completes a phase I trial in Healthy volunteers in Netherlands
- 04 May 2010 Phase-I clinical trials in Diabetes mellitus in Netherlands (IV)